Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-143079

Published: 2020

Journal Articles

Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia

Hein Than, MD FRCPath, MRCP, Anthony D. Pomicter, MS, Clinton C. Mason, PhD, Anna M. Eiring, PhD, William L. Heaton, MS, Dongqing Yan, Anna Senina, MS, Phillip M. Clair, MS, Tessa L. Holyoake, MD PhD FRCP, FRCPath, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 42.

https://doi.org/10.1182/blood.V130.Suppl_1.42.42

Published: 2017

Journal Articles

Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Gillian A. Horne, BSc hons, MBChB, MRCP, MRes, Heather Morrison, BSc hons, Victoria Campbell, BSc hons, MBBS, MRCP, FRCPath, Ross Kinstrie, PhD BSc, Jennifer Cassels, BSc hons, Alan Hair, BSc, PhD, David Vetrie, BSc, PhD, Helen Wheadon, PhD, Tessa L. Holyoake, MD PhD FRCP, FRCPath, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 3057.

https://doi.org/10.1182/blood.V128.22.3057.3057

Published: 2016

Journal Articles

Therapy Resistant CML Stem Cells Are Dependent on Mitochondrial Oxidative Metabolism for Their Survival

Elodie Marie Kuntz, Pablo Baquero, PhD, Tessa L. Holyoake, MD PhD FRCP, FRCPath, Eyal Gottlieb, PhD, G. Vignir Helgason, PhD

Blood (2016) 128 (22): 932.

https://doi.org/10.1182/blood.V128.22.932.932

Published: 2016

Journal Articles

Effective and Selective Elimination of CML Stem Cells Using Novel Ethacrynic Acid Derivatives

Su Chu, MD, YinWei Ho, Guisen Zhao, Tessa L. Holyoake, MD PhD, Samuel Waxman, MD, Yongkui Jing, PhD, Ravi Bhatia, MD

Blood (2014) 124 (21): 4508.

https://doi.org/10.1182/blood.V124.21.4508.4508

Published: 2014

Journal Articles

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Blood (2014) 124 (21): 4512.

https://doi.org/10.1182/blood.V124.21.4512.4512

Published: 2014

Journal Articles

Role of Enhanced Microenvironmental Interleukin-1 (IL-1) Expression and Increased IL-1 Responsiveness in Persistence of Leukemia Stem Cells in TKI Treated CML Patients

Bin Zhang, PhD, YinWei Ho, Tinisha McDonald, B.S., Allen Lin, David S Snyder, MD, Vu N. Ngo, PhD, Tessa L. Holyoake, MD PhD, Ravi Bhatia, MD

Blood (2014) 124 (21): 4357.

https://doi.org/10.1182/blood.V124.21.4357.4357

Published: 2014

Journal Articles

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Stefan Balabanov, MD/PhD, Artur Gontarewicz, MD, Gunhild Keller, MD, Jürgen Moll, PhD, Carsten Bokemeyer, MD, Tessa L Holyoake, MD/PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 3227.

https://doi.org/10.1182/blood.V112.11.3227.3227

Published: 2008

Journal Articles

Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.

Heiko Konig, MD, Mhairi Copland, MD, Richard Jove, PhD, Tessa L. Holyoake, MD, PhD, Ravi Bhatia, MD

Blood (2007) 110 (11): 2944.

https://doi.org/10.1182/blood.V110.11.2944.2944

Published: 2007

Journal Articles

Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment.

Bin Zhang, MD, PhD, Heiko Konig, MD, Tinisha Mcdonald, BS, Tessa L. Holyoake, MD, PhD, Dario Campana, PhD, Ravi Bhatia, MD

Blood (2007) 110 (11): 3378.

https://doi.org/10.1182/blood.V110.11.3378.3378

Published: 2007

Journal Articles

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

Mhairi Copland, MD, Linda Richmond, BSc, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Junia V. Melo, MD, PhD, Tessa L. Holyoake, MD, PhD

Blood (2006) 108 (11): 739.

https://doi.org/10.1182/blood.V108.11.739.739

Published: 2006

Journal Articles

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Mhairi Copland, MD, Ashley Hamilton, BSc, Elaine K. Allan, BSc, Valerie Brunton, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 693.

https://doi.org/10.1182/blood.V106.11.693.693

Published: 2005

Journal Articles

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Mhairi Copland, MD, Ashley Hamilton, BSc, Janet W. Baird, PhD, Martin Barow, PhD, Elaine K. Allan, BSc, Lucy J. Elrick, PhD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 695.

https://doi.org/10.1182/blood.V106.11.695.695

Published: 2005

Journal Articles

Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.

Mhairi Copland, MD, Nicholas Heaney, MD, Karen Stewart, BSc, Judith Godden, PhD, Graeme Smith, MD, Charles Crawley, MD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 1125.

https://doi.org/10.1182/blood.V106.11.1125.1125

Published: 2005

Journal Articles

Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro .

Lucy J. Elrick, PhD, Ashley Hamilton, BSc, Michael W. Deininger, MD PhD, Tessa L. Holyoake, MD PhD

Blood (2004) 104 (11): 1979.

https://doi.org/10.1182/blood.V104.11.1979.1979

Published: 2004

Journal Articles

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD, MRPharmS, Elaine K. Allan, BSc (Hons), Joanne C. Mountford, PhD, Linda Richmond, BSc(Hons), Moira A. Elliott, PhD, MRPharmS, Tessa L. Holyoake, MD, PhD

Blood (2004) 104 (11): 1997.

https://doi.org/10.1182/blood.V104.11.1997.1997

Published: 2004

Journal Articles

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Heather G. Jorgensen, PhD MRPharmS, Mhairi Copland, MD, Elaine K. Allan, BSc(Hons), Allen C. Eaves, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD, Tessa L. Holyoake, MD PhD

Blood (2004) 104 (11): 2941.

https://doi.org/10.1182/blood.V104.11.2941.2941

Published: 2004

Journal Articles

Functional ABCG2 Is Expressed on CML Stem Cells and Its Inhibition Selectively Depletes CML CD34+ Cells.

Joanne C. Mountford, PhD, Diane Gilmour, BSc, Susan M. Graham, BSc, Niove E. Jordanides, BSC, MSc, Siobhan McMillan, BSc, Tessa L. Holyoake, MD, PhD.

Blood (2004) 104 (11): 716.

https://doi.org/10.1182/blood.V104.11.716.716

Published: 2004

NARROW

A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia

Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Therapy Resistant CML Stem Cells Are Dependent on Mitochondrial Oxidative Metabolism for Their Survival

Effective and Selective Elimination of CML Stem Cells Using Novel Ethacrynic Acid Derivatives

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Role of Enhanced Microenvironmental Interleukin-1 (IL-1) Expression and Increased IL-1 Responsiveness in Persistence of Leukemia Stem Cells in TKI Treated CML Patients

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.

Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment.

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).

Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro , but Does Not Eradicate Quiescent CML Stem Cells.

Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.

Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro .

Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro .

G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro .

Functional ABCG2 Is Expressed on CML Stem Cells and Its Inhibition Selectively Depletes CML CD34+ Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only